Here are what the editors at HealthDay consider to be the most important developments in HIV & AIDS for June 2006. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.
FDA Warns of Ketek-Associated Liver Problems
FRIDAY, June 30 (HealthDay News) -- The U.S. Food and Drug Administration has issued a warning to health care professionals and patients to be aware of the potential of rare, but serious risks of liver injury with the antibiotic Ketek (telithromycin).
More Information
CDC Reports 1.2 Percent of Rapid HIV Tests Positive
THURSDAY, June 29 (HealthDay News) -- About 1.2 percent of the nearly 373,000 rapid HIV tests conducted in the United States between September 2003 and December 2005 were confirmed HIV-positive, according to a report in the June 23 issue of the Morbidity and Mortality Weekly Report.
More Information
FDA Tentatively Approves Generic Pediatric AIDS Drug
WEDNESDAY, June 28 (HealthDay News) -- The U.S Food and Drug Administration has tentatively approved the first generic version of abacavir sulfate oral solution, for use in HIV-infected pediatric patients from 3 months to 13 years.
More Information
FDA Approves Prezista, A New Protease Inhibitor for HIV
MONDAY, June 26 (HealthDay News) -- The U.S. Food and Drug Administration has approved darunavir (Prezista), a new protease inhibitor for use in treating HIV-infected adults who have not responded to other antiretroviral drugs. The drug is approved for co-administration with a low dose of ritonavir (as well as other anti-HIV agents), which increases the concentration of Prezista in the patient's system by slowing its absorption.
More Information
Primate Study Suggests Reason for HIV-1 Virulence
MONDAY, June 19 (HealthDay News) -- A study of primate viruses suggests that over time, HIV's Nef protein lost the ability to suppress T-cell activation and downregulate the expression of the T-cell receptor-CD3 complex, possibly allowing it to become more virulent by enhancing activation-induced cell death in infected T cells, according to a study in the June 15 issue of Cell.
Abstract
Full Text
Editorial
Milk Intake Has No Impact on HIV-Related Diarrhea
WEDNESDAY, June 14 (HealthDay News) -- HIV-infected patients can consume moderate amounts of dairy products, regardless of their lactase status, without risking a worsening of HIV-related diarrhea, according to a study published in the June issue of the Archives of Internal Medicine.
Abstract
Full Text
HIV-Positive Women Benefit from Supervised Exercise
WEDNESDAY, June 14 (HealthDay News) -- HIV-infected women who joined a 16-week, home-based program of exercise under supervision gained several benefits, notably improved strength, as well as better endurance, body composition and cardiorespiratory fitness, according to a study in the June issue of the Archives of Internal Medicine.
Abstract
Full Text (subscription or payment may be required)
Vaccine Prolongs Survival After SIV Challenge in Monkeys
FRIDAY, June 9 (HealthDay News) -- Monkeys vaccinated with plasmid DNA and an adenovirus vector that expresses simian immunodeficiency virus (SIV) proteins show increased survival after an SIV challenge that is associated with a stronger initial T-cell response and preservation of memory CD4+ T cells, according to a report in the June 9 issue of Science.
Abstract
Full Text (subscription or payment may be required)
Many Adolescent Girls Report Having Unwanted Sex
MONDAY, June 5 (HealthDay News) -- About 40 percent of adolescent girls report being pressured or threatened into having sex, according to a study in the June issue of the Archives of Pediatrics & Adolescent Medicine.
Abstract
Full Text (subscription or payment may be required)
